胃淋巴瘤免疫治疗研究的进展  

Advances in immunotherapy for gastric lymphoma

作　　者：王亮[1] 王进峰 李亚军 左朝晖[1,2,3] Wang Liang;Wang Jinfeng;Li Yajun;Zuo Chaohui(Graduates School,University of South China,Hengyang 421001,Hunan,China;Department of Gastroduodenal and Pancreatic Surgery,Affiliated Cancer Hospital of Xiangya Medical School,Central South University&Hunan Province Cancer Hospital,Hunan Province Key Laboratory of Virology(Tumor immunity),Changsha 410013,Hunan,China;Translational Medicine Research Center of Liver Cancer,Laboratory of Digestive Oncology,Hunan Province Cancer Hospital(Hunan Province Cancer Institute),Changsha 410013,Hunan,China)

机构地区：[1]南华大学研究生院,湖南衡阳421001 [2]湖南省肿瘤医院暨中南大学湘雅医学院附属肿瘤医院胃十二指肠胰腺外科,湖南长沙410013 [3]湖南省肿瘤医院渊湖南省肿瘤防治研究所冤肝癌转化医学联合研究中心和消化道肿瘤实验室,湖南长沙410013

出　　处：《消化肿瘤杂志（电子版）》2020年第1期12-16,共5页Journal of Digestive Oncology(Electronic Version)

基　　金：2017年湖南省科技厅重点研发计划项目(2017k2130)。

摘　　要：恶性淋巴瘤是淋巴细胞恶变形成的恶性肿瘤,是世界上流行较广的血液系统恶性肿瘤,其发病率和死亡率一直呈上升趋势。本文综述了近年来靶向淋巴细胞分化抗原单抗,嵌合抗原受体T细胞(chimeric antigen receptor T-cell,CAR-T)和免疫检查点阻断剂等多种免疫治疗方法在胃淋巴瘤治疗中的研究进展。Lymphoma is a worldwide lymphocyte derived hematological malignant tumor.Its morbidity and mortality has been on the rise.In this review,we summarized the most recent advances and main studies on immunotherapy in patients with primary gastric lymphoma,including monoclinal antibody of cluster of differentiation targeting lymphocyte,chimeric antigen receptor T-cell(CAR-T)and immune checkpoint inhibitors(such as PD-L1 monoclinal antibody).

关 键 词：胃淋巴瘤 免疫治疗 程序性死亡配体1 嵌合抗原受体T细胞 

分 类 号：R735.2[医药卫生—肿瘤]